Alkhalifah, A., Alsantali, A., Wang, E., McElwee, K. J., & Shapiro, J. (2010). Alopecia areata update. Part I. Clinical picture, histopathology, and pathogenesis. Journal of the American Academy of Dermatology, 62(2), 177–188.
Gamal, N., Brodosi, L., Misciali, C., Patrizi, A., Vukatana, G., Malavolta, N., ¡¦ Andreone, P. (2014). Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. Ann Hepatol, 13(2), 293–296.
Gamal, N., Brodosi, L., Misciali, C., Patrizi, A., Vukatana, G., Malavolta, N., ¡¦ Andreone, P. (2014). Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. Ann Hepatol, 13(2), 293–296.
Go, J. W., Kim, S. H., Lee, S. Y., In, B., Cho, H. K., & Hospital, M. (2011). P148 Clinical study of alopecia areata in children (2007-2011). ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ ÃÊ·ÏÁý (Vol. 63, pp. 200–201).
Information Sheet Observed Rate of Vaccine Reactions Influenza Vaccine. (2012) WHO.
Islam, N., Leung, P. S. C., Huntley, A. C., & Eric Gershwin, M. (2015). The autoimmune basis of alopecia areata: A comprehensive review. Autoimmunity Reviews, 14(2), 81–89.
Omazzi, B., Prada, A., Borroni, G., & Sacrini, F. (2012). Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review. Hepatology Research, 42(12), 1248–1251.
Parker, V., Wong, A. H. C., Boon, H. S., & Seeman, M. V. (2001). Adverse reactions to St John¡¯s Wort. Can J Psychiatry, 46, 77–79.
Shin, H.-K., Jeong, S.-J., Lee, M. S., & Ernst, E. (2013). Adverse events attributed to traditional Korean medical practices: 1999-2010. Bulletin of the World Health Organization, 91(8), 569–75.
Tengstrand, M., & Star, K. (2010). Alopecia in Association with Lamotrigine Use. Drug Saf 2010, 33(8), 653–658.
Watras, M. M., Patel, J. P., & Arya, R. (2016). Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature. Drugs – Real World Outcomes, 3(1), 1–6.